Literature DB >> 8353493

Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy.

A V Winnard1, C J Klein, D D Coovert, T Prior, A Papp, P Snyder, D E Bulman, P N Ray, P McAndrew, W King.   

Abstract

The clinical progression of Duchenne muscular dystrophy (DMD) patients with deletions can be predicted in 93% of cases by whether the deletion maintains or disrupts the translational reading frame (frameshift hypothesis). We have identified and studied a number of patients who have deletions that do not conform to the translational frame hypothesis. The most common exception to the frameshift hypothesis is the deletion of exons 3 to 7 which disrupts the translational reading frame. We identified a Becker muscular dystrophy (BMD) patient, an intermediate, and a DMD patient with this deletion. In all three cases, dystrophin was detected and localized to the membrane. One DMD patient with an inframe deletion of exons 4-18 produced no dystrophin. One patient with a mild intermediate phenotype and a deletion of exon 45, which shifts the reading frame, produced no dystrophin. Two patients with large inframe deletions had discordant phenotypes (exons 3-41, DMD; exons 13-48, BMD), but both produced dystrophin that localized to the sarcolemma. The DMD patient, 113, indicates that dystrophin with an intact carboxy terminus can be produced in Duchenne patients at levels equivalent to some Beckers. The dystrophin analysis from these patients, together with patients reported in the literature, indicate that more than one domain can localize dystrophin to the sarcolemma. Lastly, the data shows that although most patients show correlation of clinical severity to molecular data, there are rare patients which do not conform.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353493     DOI: 10.1093/hmg/2.6.737

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  34 in total

1.  Alternative splicing of dystrophin exon 4 in normal human muscle.

Authors:  S Torelli; F Muntoni
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

Review 2.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

3.  Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.

Authors:  Emanuela Gussoni; Richard R Bennett; Kristina R Muskiewicz; Todd Meyerrose; Jan A Nolta; Irene Gilgoff; James Stein; Yiu-Mo Chan; Hart G Lidov; Carsten G Bönnemann; Arpad Von Moers; Glenn E Morris; Johan T Den Dunnen; Jeffrey S Chamberlain; Louis M Kunkel; Kenneth Weinberg
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

4.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

5.  An intragenic deletion/inversion event in the DMD gene determines a novel exon creation and results in a BMD phenotype.

Authors:  Rachele Cagliani; Manuela Sironi; Emma Ciafaloni; Alessandra Bardoni; Francesco Fortunato; Alessandro Prelle; Massimo Serafini; Nereo Bresolin; Giacomo P Comi
Journal:  Hum Genet       Date:  2004-04-30       Impact factor: 4.132

6.  Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice.

Authors:  Bo Wu; Yongfu Li; Paul A Morcos; Timothy J Doran; Peijuan Lu; Qi Long Lu
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

7.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Deletions in the 5' region of dystrophin and resulting phenotypes.

Authors:  F Muntoni; P Gobbi; C Sewry; T Sherratt; J Taylor; S K Sandhu; S Abbs; R Roberts; S V Hodgson; M Bobrow
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

9.  Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco.

Authors:  Hanane Bellayou; Khalil Hamzi; Mohamed Abdou Rafai; Mehdi Karkouri; Ilham Slassi; Houssine Azeddoug; Sellama Nadifi
Journal:  J Biomed Biotechnol       Date:  2009-05-19

10.  microRNAs and genetic diseases.

Authors:  Nicola Meola; Vincenzo Alessandro Gennarino; Sandro Banfi
Journal:  Pathogenetics       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.